There are 645 papers on hypoglycemia in aging research: 156 trials and 175 observational studies in people, 40 in animals, 255 reviews.
55 new papers in 30 daysSee all 816 papers on hypoglycemia
“Semaglutide increased the risk of hypoglycemia compared to placebo”
- Human trial156
- Humans175
- Animals38
- Model organisms2
- In silico7
Interventions
42Tirzepatide
no changein humans8downin humans6RR 0.46
14 studies
Tirzepatide
no changein humans8downin humans6RR 0.46
Tirzepatide showed no clear effect on hypoglycemia in humans during Ramadan fasting (none reported).
Human trialduring Ramadan fasting2.5 mg weeklyn = 109
Tirzepatide decreases hypoglycemia in humans (compared with insulin glargine).
Human trialcompared with insulin glargine5, 10, or 15 mg104 weeksn = 1,500
Tirzepatide showed no clear effect on hypoglycemia in humans.
Human trialolder adults without obesity (BMI < 30 kg/m2); regardless of concurrent insulin or sulfonylurea use
Tirzepatide decreases hypoglycemia in humans (added to insulin glargine, compared with insulin lispro added to insulin glargine) (0.4 vs 4.4 events per patient-year).
Human trialadded to insulin glargine, compared with insulin lispro added to insulin glargine
Tirzepatide showed no clear effect on hypoglycemia in participants achieving HbA1c <5.7%.
Human trialin participants achieving HbA1c <5.7%40 weeks
Tirzepatide showed no clear effect on hypoglycemia in humans (baseline HbA1c >8.5% versus ≤8.5%).
Human trialbaseline HbA1c >8.5% versus ≤8.5%5, 10 or 15 mg52 weeks
Tirzepatide decreases hypoglycemia in humans (versus insulin).
Human trialversus insulin15 mg
Tirzepatide decreases hypoglycemia in humans (versus insulin glargine) (6-9% vs 19% with glargine).
Human trialversus insulin glargine52 weeks
Tirzepatide showed no clear effect on hypoglycemia in humans (monotherapy in type 2 diabetes).
Human trialmonotherapy in type 2 diabetesonce-weekly5, 10, or 15 mg40 weeksn = 478
Tirzepatide was not clearly linked with hypoglycemia in humans (severe hypoglycaemia in type 1 diabetes and obesity).
Humanssevere hypoglycaemia in type 1 diabetes and obesity5 mg weekly12 months
All 14Fewer
GLP-1 receptor agonists
no changein humans6downin humans2HR 1.1
8 studies
GLP-1 receptor agonists
no changein humans6downin humans2HR 1.1
GLP-1 receptor agonists showed no clear effect on hypoglycemia in humans (add-on to metformin in type 2 diabetes).
Human trialadd-on to metformin in type 2 diabetes
GLP-1 receptor agonists showed no clear effect on hypoglycemia in humans.
Human trialas part of glucose-dependent strategy (with nonsulfonylurea OAM) vs sulfonylurea and insulin glargine24 weeksn = 26
GLP-1 receptor agonists decrease hypoglycemia in humans (compared with sulfonylurea and insulin glargine strategy) (total 10.2% vs 53.8%; P < .001).
Human trialcompared with sulfonylurea and insulin glargine strategy
GLP-1 receptor agonists were not clearly linked with hypoglycemia in humans (Type 2 diabetes and CKD stages 2–4; compared with DPP-4 inhibitors).
HumansType 2 diabetes and CKD stages 2–4; compared with DPP-4 inhibitors
GLP-1 receptor agonists were not clearly linked with hypoglycemia in humans (propensity-matched comparison with non-GLP-1 users) (HR 1.10 (95% CI 0.60-1.76)).
Humanspropensity-matched comparison with non-GLP-1 users12 monthsn = 1,391
GLP-1 receptor agonists decrease hypoglycemia in humans.
Review
GLP-1 receptor agonists showed no clear effect on hypoglycemia in humans.
Review
GLP-1 receptor agonists showed no clear effect on hypoglycemia in humans (added to basal insulin, compared with rigorously titrated basal insulin alone) (RR 1.01, 95% CI 0.86 to 1.18).
Reviewadded to basal insulin, compared with rigorously titrated basal insulin alone
Acarbose
no changein humans4downin humans2upin humans1
7 studies
Acarbose
no changein humans4downin humans2upin humans1
Acarbose decreases hypoglycemia in humans (2 vs 13 patients).
Human trial6 months
Acarbose decreases hypoglycemia in H-MAGE patients on twice-daily premixed insulin aspart 30 (2% vs. 24%, χ(2) = 9.61, P < 0.01).
Human trialin H-MAGE patients on twice-daily premixed insulin aspart 302 weeksn = 86
Acarbose showed no clear effect on hypoglycemia in humans.
Human trial3 yearsn = 1,946
Acarbose showed no clear effect on hypoglycemia in humans (added to insulin).
Human trialadded to insulin24 weeks
Acarbose showed no clear effect on hypoglycemia in humans (added to diet and insulin therapy).
Human trialadded to diet and insulin therapy36 weeks
Acarbose induces hypoglycemia in humans (non-insulin-dependent diabetic patients) (12 patients).
Human trialnon-insulin-dependent diabetic patientsn = 90
Acarbose showed no clear effect on hypoglycemia in humans.
Review
Linagliptin
no changein humans5OR 1.12
5 studies
Linagliptin
no changein humans5OR 1.12
Linagliptin showed no clear effect on hypoglycemia in humans.
Human trial
Linagliptin showed no clear effect on hypoglycemia in humans (compared with placebo).
Human trialcompared with placebo5 mg qd24 weeks
Linagliptin showed no clear effect on hypoglycemia in humans (all-patient population, 24 weeks, versus placebo) (HR 1.07; 95% CI 0.84–1.36; P = 0.5943).
Human trialall-patient population, 24 weeks, versus placebo5 mg24 weeksn = 1,489
Linagliptin showed no clear effect on hypoglycemia in humans (patients not taking sulfonylureas) (1.2% linagliptin vs 1.1% placebo).
Human trialpatients not taking sulfonylureas5 mg/d24 weeks
Linagliptin showed no clear effect on hypoglycemia in humans (type 2 diabetes mellitus) (OR 1.12, 95% CI: 0.85, 1.48).
Reviewtype 2 diabetes mellitus24 weeks
Semaglutide
downin humans1upin humans1no changein humans1
3 studies
Semaglutide
downin humans1upin humans1no changein humans1
Semaglutide induces hypoglycemia in an occult insulinoma patient (35 mg/dL).
Human trialin an occult insulinoma patientfemalesn = 1
Semaglutide showed no clear effect on hypoglycemia in humans (non-elderly and elderly patients with type 2 diabetes).
Human trialnon-elderly and elderly patients with type 2 diabetesonce-weekly subcutaneous0.5 and 1.0 mg
Semaglutide is linked with lower hypoglycemia in one patient with recurrent hypoglycemia and poorly controlled diabetes.
Humansin one patient with recurrent hypoglycemia and poorly controlled diabetesmalesn = 1
SGLT2 inhibitors
no changein humans3
3 studies
SGLT2 inhibitors
no changein humans3
SGLT2 inhibitors showed no clear effect on hypoglycemia in patients with HFrEF without diabetes.
Human trialin patients with HFrEF without diabetesthree monthsn = 130
SGLT2 inhibitors were not clearly linked with hypoglycemia in humans (versus new DPP4i, 30-day risk).
Humansversus new DPP4i, 30-day risk30 days
SGLT2 inhibitors showed no clear effect on hypoglycemia in hypertensive patients with diabetes.
Reviewin hypertensive patients with diabetes
Empagliflozin
no changein humans2
2 studies
Empagliflozin
no changein humans2
Empagliflozin showed no clear effect on hypoglycemia in individuals with HNF1A-MODY as add-on treatment.
Human trialin individuals with HNF1A-MODY as add-on treatment25 mg4 weeksn = 18
Drug lowered blood sugar in an inherited form of diabetes
Diabetes careEmpagliflozin showed no clear effect on hypoglycemia in humans (adjunctive to automated insulin delivery).
Reviewadjunctive to automated insulin delivery
Dapagliflozin
upin humans2
2 studies
Dapagliflozin
upin humans2
Dapagliflozin increases hypoglycemia in older patients, by age stratum (20.2 vs 17.7% (≥65 years)).
Human trialin older patients, by age stratum10 mgup to 104 weeks
Dapagliflozin is linked with hypoglycemia in humans.
Humansin a nondiabetic patient with end-stage familial hypertrophic cardiomyopathy and MYH7 mutationsfemales
GLP-1 receptor agonists + SGLT2 inhibitors
no changein humans2HR 0.799
2 studies
GLP-1 receptor agonists + SGLT2 inhibitors
no changein humans2HR 0.799
GLP-1 receptor agonists + SGLT2 inhibitors showed no clear effect on hypoglycemia in humans (compared with monotherapy).
Human trialcompared with monotherapy
GLP-1 receptor agonists + SGLT2 inhibitors showed no clear effect on hypoglycemia in humans (versus SGLT2 inhibitors alone) (1.3% vs 1.7%; HR 0.799).
Reviewversus SGLT2 inhibitors alone365 days after treatment initiationn = 1,118
Sulfonylureas
upin humans2
2 studies
Sulfonylureas
upin humans2
Sulfonylureas induce hypoglycemia in patients with compensated cirrhosis.
Reviewin patients with compensated cirrhosis
Sulfonylureas induce hypoglycemia in humans.
Review
Liraglutide
no changein humans2
2 studies
Liraglutide
no changein humans2
Liraglutide showed no clear effect on hypoglycemia in humans.
Human trial1.2 mg3 weeksfemalesn = 11
Liraglutide showed no clear effect on hypoglycemia in humans (added to insulin therapy).
Human trialadded to insulin therapy6 monthsn = 20
Diet
no changein humans1
1 study
Diet
no changein humans1
Diet showed no clear effect on hypoglycemia in humans (1.4 percentage points (95% CI -1.0, 3.7)).
Human trialthree monthsn = 28
Diet showed no clear effect on hypoglycemia in humans (type 1 diabetes with overweight or obesity) (P > .05).
Human trialtype 1 diabetes with overweight or obesity3 monthsn = 28
Metformin + dapagliflozin + saxagliptin
downin humans1
1 study
Metformin + dapagliflozin + saxagliptin
downin humans1
Metformin + dapagliflozin + saxagliptin decreases hypoglycemia in humans (Newly diagnosed type 2 diabetes; compared with stepwise add-on therapy).
Human trialNewly diagnosed type 2 diabetes; compared with stepwise add-on therapy104 weeks
Sitagliptin + empagliflozin
no changein humans1
1 study
Sitagliptin + empagliflozin
no changein humans1
Sitagliptin + empagliflozin showed no clear effect on hypoglycemia in humans (add-on to metformin and sitagliptin, versus placebo).
Human trialadd-on to metformin and sitagliptin, versus placebofixed-dose combination24 weeksn = 230
HRS-7535
upin humans1
1 study
HRS-7535
upin humans1
HRS-7535 induces hypoglycemia in humans (treatment-emergent, documented hypoglycemia) (5.8% (9 pts); no Level 2 or higher events).
Human trialtreatment-emergent, documented hypoglycemiaoral small molecule15–90 mg16 weeks
All 42Fewer
Effects
8Cognitive function
downin humans2
2 studies
Cognitive function
downin humans2
Hypoglycemia impairs cognitive function in seniors.
Reviewin seniors
Hypoglycemia impairs cognitive function in older diabetic patients (SMD 0.58, 95% CI 0.88-0.28).
Reviewin older diabetic patients
Hospital readmissions
upin humans1
1 study
Hospital readmissions
upin humans1
Hypoglycemia is linked with higher hospital readmissions in humans (hospitalized older adults, 1:2 propensity score matched) (IRR=2.019, 95 % CI: 1.970-2.069).
Humanshospitalized older adults, 1:2 propensity score matched
Cardiac injury
upin reviews1
1 study
Cardiac injury
upin reviews1
Hypoglycemia increases cardiac injury (recurrent hypoglycemia).
Reviewrecurrent hypoglycemiaheartchronic
Electrophysiological disturbances
upin reviews1
1 study
Electrophysiological disturbances
upin reviews1
Hypoglycemia induces electrophysiological disturbances.
Reviewheartacute
nNOS gene expression
upin rats1
1 study
nNOS gene expression
upin rats1
Hypoglycemia increases nNOS gene expression in rats.
AnimalsVMNdm Ghrh neuron
Cardiovascular consequences
upin reviews1
1 study
Cardiovascular consequences
upin reviews1
Hypoglycemia increases cardiovascular consequences in older adults submitted to tight glycemic control.
Reviewin older adults submitted to tight glycemic control
Cognitive dysfunction
no changein humans1
1 study
Cognitive dysfunction
no changein humans1
Hypoglycemia was not clearly linked with cognitive dysfunction in humans (P=0.1106).
HumansKorean patients with type 2 diabetes mellitus; hypoglycemic events versus no hypoglycemic eventsMean follow-up of 3.4±0.9 yearsn = 1,957
Counter-regulatory responses to hypoglycemia
downin humans1
1 study
Counter-regulatory responses to hypoglycemia
downin humans1
Hypoglycemia impairs counter-regulatory responses to hypoglycemia in humans (frequent hypoglycemic episodes in diabetic patients).
Reviewfrequent hypoglycemic episodes in diabetic patients
Upstream
7Older age
no changein humans1
1 study
Older age
no changein humans1
Older age was not clearly linked with hypoglycemia in humans (hospitalized in non-acute settings).
Humanshospitalized in non-acute settings
AstC-R2
downin flies1
1 study
AstC-R2
downin flies1
AstC-R2 protects against hypoglycemia in flies during fasting.
Model organismsduring fastingadipokinetic-hormone-producing cells
HbA1c
no changein humans1OR 0.95
1 study
HbA1c
no changein humans1OR 0.95
HbA1c was not clearly linked with hypoglycemia in humans (dementia and T2DM) (OR = 0.95, p = 0.140).
Humansdementia and T2DMtwo-yearn = 3,877
Lactate
downin mice1
1 study
Lactate
downin mice1
Lactate prevents hypoglycemia in mice after calorie restriction and 23-hour fast.
Animalsafter calorie restriction and 23-hour fast
GHR
downin mice1
1 study
GHR
downin mice1
GHR prevents hypoglycemia in mice (shown by liver-specific knockout after calorie restriction and 23-hour fast).
Animalsshown by liver-specific knockout after calorie restriction and 23-hour fastliver
Age
no changein humans1
1 study
Age
no changein humans1
Age showed no clear effect on hypoglycemia in humans (age <65 vs ≥65 years, with insulin glargine).
Human trialage <65 vs ≥65 years, with insulin glargine
Ghrelin
downin mice1
1 study
Ghrelin
downin mice1
Ghrelin protects against hypoglycemia in beta1AR-deficient mice under severe caloric restriction.
Animalsin beta1AR-deficient mice under severe caloric restriction
Associations
75GLP-1 receptor agonists
upin humans7downin humans3downin reviews1RR 1.263
11 studies
GLP-1 receptor agonists
upin humans7downin humans3downin reviews1RR 1.263
GLP-1 receptor agonists raise the risk of hypoglycemia in humans (older vs younger adults) (LOR 0.97, p < 0.001).
Human trialolder vs younger adults
GLP-1 receptor agonists raise the risk of hypoglycemia in humans (adjunctive to insulin in type 1 diabetes with overweight or obesity) (OR 1.32 (95% CI 1.01 to 1.72)).
Human trialadjunctive to insulin in type 1 diabetes with overweight or obesity
GLP-1 receptor agonists are linked with a higher risk of hypoglycemia in humans (obesity and heart failure) (RR 1.263, 95% CI 1.169-1.364).
Humansobesity and heart failure5 years
Drugs linked to falls in older adults with obesity and heart failure
AHA Scientific Sessions 2026 abstractGLP-1 receptor agonists are linked with a higher risk of hypoglycemia in adults surviving dialysis-requiring acute kidney injury (OR 5.4 (95% CI 4.87-5.99)).
Humansin adults surviving dialysis-requiring acute kidney injury
GLP-1 receptor agonists are linked with a higher risk of hypoglycemia in humans (when combined with anabolic-androgenic steroids).
Humanswhen combined with anabolic-androgenic steroids
GLP-1 receptor agonists are linked with a lower risk of hypoglycemia in humans (versus sulfonylureas) (HR 0.21 (95% CI 0.16-0.27)).
Humansversus sulfonylureas
GLP-1 receptor agonists are associated with hypoglycemia in humans after spine surgery; perioperative exposure.
Reviewafter spine surgery; perioperative exposure
GLP-1 receptor agonists raise the risk of hypoglycemia in type 1 diabetes phase 3 trials.
Reviewin type 1 diabetes phase 3 trialsdaily injectable
GLP-1 receptor agonists lower the risk of hypoglycemia in humans (type 2 diabetes).
Reviewtype 2 diabetes
GLP-1 receptor agonists lower the risk of hypoglycemia in humans (type 2 diabetes).
Reviewtype 2 diabetes
All 11Fewer
Insulin
upin humans7upin silico1OR 4.22–4.64
8 studies
Insulin
upin humans7upin silico1OR 4.22–4.64
Insulin is associated with hypoglycemia in humans (average 0.13% per month).
Humans
Insulin is linked with a higher risk of hypoglycemia in humans (hospitalized patients with type 2 diabetes) (OR 4.22, 95% CI 2.14-6.28).
Humanshospitalized patients with type 2 diabetes
Insulin is linked with a higher risk of hypoglycemia in humans (dementia and T2DM) (OR = 4.64, p < 0.001).
Humansdementia and T2DMtwo-yearn = 3,877
Insulin is linked with a higher risk of hypoglycemia in humans (patients aged over 65 on insulin versus sulfonylureas) (34% vs 5% with more than one documented episode (sulphonylurea); 2% metformin-only; p<0.001).
Humanspatients aged over 65 on insulin versus sulfonylureasn = 79
Insulin is linked with a higher risk of hypoglycemia in patients with type 2 diabetes.
Humansin patients with type 2 diabetes
Insulin raises the risk of hypoglycemia in elderly individuals with type 2 diabetes.
Reviewin elderly individuals with type 2 diabetes
Insulin raises the risk of hypoglycemia in humans.
Review
Insulin raises the risk of hypoglycemia in silico (modeled drug-induced hypoglycemia) (8.64 events per person-year (65-79 years); 12.06 events per person-year (80 years and older)).
In silicomodeled drug-induced hypoglycemiabasal
SGLT2 inhibitors
downin humans6upin humans1RR 0.27–0.53
7 studies
SGLT2 inhibitors
downin humans6upin humans1RR 0.27–0.53
SGLT2 inhibitors are linked with a higher risk of hypoglycemia in adults with type 2 diabetes mellitus undergoing open surgical tracheostomy (OR 2.01, 95% CI 1.30-3.13).
Humansin adults with type 2 diabetes mellitus undergoing open surgical tracheostomy180 days
SGLT2 inhibitors are linked with a lower risk of hypoglycemia in humans (versus sulfonylureas) (HR 0.21 (95% CI 0.13-0.33)).
Humansversus sulfonylureas
SGLT2 inhibitors are linked with a lower risk of hypoglycemia in humans (versus dpp-4 inhibitor users) (HR 0.61; RD -1.6 per 1000 person-years).
Humansversus dpp-4 inhibitor usersn = 29,916
SGLT2 inhibitors are linked with a lower risk of hypoglycemia in humans (new users compared with sulfonylurea initiation, after propensity score decile adjustment).
Humansnew users compared with sulfonylurea initiation, after propensity score decile adjustment
SGLT2 inhibitors lower the risk of hypoglycemia in humans (fasting during Ramadan) (RR 0.53, 95% CI 0.29-0.97).
Reviewfasting during Ramadan
SGLT2 inhibitors lower the risk of hypoglycemia in humans (RR 0.27, 95% CI 0.09–0.84).
ReviewWith metformin in type 2 diabetes mellitus, compared with other metformin-containing oral dual therapies52 weeks
SGLT2 inhibitors lower the risk of hypoglycemia in humans (type 2 diabetes).
Reviewtype 2 diabetes
Tirzepatide
upin humans4downin humans3RR 0.46–3.83
7 studies
Tirzepatide
upin humans4downin humans3RR 0.46–3.83
Tirzepatide lowers the risk of hypoglycemia in humans (add-on to oral anti-hyperglycemic drugs, versus once-daily basal insulin).
Human trialadd-on to oral anti-hyperglycemic drugs, versus once-daily basal insulin
Tirzepatide is associated with hypoglycemia in humans (most hypoglycemic subjects were insulin users).
Humansmost hypoglycemic subjects were insulin users6 monthsn = 55
Tirzepatide is associated with hypoglycemia in humans (115 cases).
Humans
Tirzepatide is associated with hypoglycemia in humans after switch from GLP-1 RA with concurrent insulin therapy (8 patients (12.1%)).
Humansafter switch from GLP-1 RA with concurrent insulin therapy6 monthsn = 66
Tirzepatide lowers the risk of hypoglycemia in humans (compared with daily insulin glargine and degludec) (RR 0.46, 95% CI (0.28, 0.75)).
Reviewcompared with daily insulin glargine and degludeconce-weekly
Tirzepatide lowers the risk of hypoglycemia in humans (versus iDegLira) (vs iDegLira OR 0.35, 95% CI 0.16–0.79).
Reviewversus iDegLira15 mg
Tirzepatide raises the risk of hypoglycemia in humans (pooled across nine RCTs) (pooled RR=3.83, 95% CI 1.19–12.30, P=0.02).
Reviewpooled across nine RCTs15 mg
DPP-4 inhibitors
downin humans4upin humans2RR 1.08
6 studies
DPP-4 inhibitors
downin humans4upin humans2RR 1.08
DPP-4 inhibitors are linked with a lower risk of hypoglycemia in residents of LTCFs with diabetes receiving metformin compared with long-acting insulin (sHR 0.36 (95% CI, 0.23-0.56)).
Humansin residents of LTCFs with diabetes receiving metformin compared with long-acting insulin5-year follow-upn = 4,414
DPP-4 inhibitors are linked with a lower risk of hypoglycemia in humans (nursing home residents) (HR = 0.57, 95% CI 0.34-0.94).
Humansnursing home residents1 yearn = 2,016
DPP-4 inhibitors lower the risk of hypoglycemia in older adults with type 2 diabetes.
Reviewin older adults with type 2 diabetes
DPP-4 inhibitors lower the risk of hypoglycemia in humans (type 2 diabetes).
Reviewtype 2 diabetes
DPP-4 inhibitors raise the risk of hypoglycemia in addition to standard care in older patients with type 2 diabetes (RR 1.08, 95% CI 1.01-1.16).
Reviewin addition to standard care in older patients with type 2 diabetesn = 19,317
DPP-4 inhibitors raise the risk of hypoglycemia in addition to standard care (RR 1.08; 95%CI 1.01-1.16).
Reviewin addition to standard care
Frailty
upin humans5
5 studies
Frailty
upin humans5
Hypoglycemia is associated with frailty in humans.
Humanselderly inpatients with diabetes; indirect association through malnutrition or risk of malnutritionn = 427
Frailty is linked with a higher risk of hypoglycemia in humans (type 2 diabetes).
Humanstype 2 diabetes
Frailty is associated with hypoglycemia in humans (diabetes).
Reviewdiabetes
Hypoglycemia raises the risk of frailty in older people with diabetes.
Reviewin older people with diabetes
Frailty raises the risk of hypoglycemia in humans (diabetes).
Reviewdiabetes
Sulfonylureas
upin humans3upin silico1upin reviews1+45%
5 studies
Sulfonylureas
upin humans3upin silico1upin reviews1+45%
Sulfonylureas are associated with hypoglycemia in humans (type 2 diabetes mellitus on sulfonylureas) (45%).
Humanstype 2 diabetes mellitus on sulfonylureasn = 40
Sulfonylureas are linked with a higher risk of hypoglycemia in patients with type 2 diabetes.
Humansin patients with type 2 diabetes
Sulfonylureas raise the risk of hypoglycemia.
Review
Sulfonylureas raise the risk of hypoglycemia in humans.
Review
Sulfonylureas raise the risk of hypoglycemia in silico (modeled drug-induced hypoglycemia) (4.32 events per person-year (65-79 years); 6.03 events per person-year (80 years and older)).
In silicomodeled drug-induced hypoglycemia
Liraglutide
downin humans3upin humans1HR 0.891
4 studies
Liraglutide
downin humans3upin humans1HR 0.891
Liraglutide lowers the risk of hypoglycemia in humans (compared with traditional antidiabetic drugs).
Human trialcompared with traditional antidiabetic drugs
Liraglutide lowers the risk of hypoglycemia in humans (0.03–0.14 vs 1.23 events/year).
Human trial26 weeksn = 1,091
Liraglutide is linked with a lower risk of hypoglycemia in humans (versus dulaglutide, propensity-matched cohort) (HR 0.891 (95% CI 0.808-0.983)).
Humansversus dulaglutide, propensity-matched cohort1 yearn = 36,851
Liraglutide raises the risk of hypoglycemia in humans (adjunct use in T1DM; dose-dependent).
Reviewadjunct use in T1DM; dose-dependent
Dementia
upin humans3HR 2.689
3 studies
Dementia
upin humans3HR 2.689
Hypoglycemia is associated with dementia in humans (Korean patients with type 2 diabetes mellitus; multiple-adjusted analysis) (HR 2.689, 95% CI 1.080–6.694; P=0.0335).
HumansKorean patients with type 2 diabetes mellitus; multiple-adjusted analysisMean follow-up of 3.4±0.9 yearsn = 1,957
Hypoglycemia raises the risk of dementia in the elderly.
Reviewin the elderly
Hypoglycemia raises the risk of dementia in humans.
Review
Cognitive impairment
upin humans3
3 studies
Cognitive impairment
upin humans3
Hypoglycemia is associated with cognitive impairment in humans.
Humanshistory of hypoglycemia in inpatients with diabetes mellitus; multivariable logistic regressionn = 87
Hypoglycemia is associated with cognitive impairment in humans (diabetes mellitus) (AOR 2.87, 95% CI 1.62–5.06).
Humansdiabetes mellitusn = 415
Hypoglycemia is linked with a higher risk of cognitive impairment in patients with T2DM.
Humansin patients with T2DMn = 240
Semaglutide
upin humans1mixedin humans1downin reviews1
3 studies
Semaglutide
upin humans1mixedin humans1downin reviews1
Semaglutide raises the risk of hypoglycemia in humans (compared with placebo).
Human trialcompared with placebo
Semaglutide is associated with hypoglycemia in humans (add-on to SGLT2i and metformin) (hypoglycemic events fell to none in 3 patients and rose in 4 patients).
Human trialadd-on to SGLT2i and metforminoraltwo weeksn = 10
Semaglutide lowers the risk of hypoglycemia.
Revieworal
Insulin glargine + lixisenatide
downin humans2
2 studies
Insulin glargine + lixisenatide
downin humans2
Insulin glargine + lixisenatide lowers the risk of hypoglycemia in humans during Ramadan fasting.
Human trialduring Ramadan fasting
Insulin glargine + lixisenatide is linked with a lower risk of hypoglycemia in humans (type 2 diabetes, ethnic minorities) (2.5 vs 3.8 vs 7.5 per 100 person-years).
Humanstype 2 diabetes, ethnic minoritiesup to 12 months
Linagliptin
downin humans1upin humans1
2 studies
Linagliptin
downin humans1upin humans1
Linagliptin raises the risk of hypoglycemia in humans (11.9% linagliptin vs 7.3% placebo).
Human trialoverall incidence, attributed to more sulfonylurea use in the linagliptin group (26.8% vs 18.4%)5 mg/d24 weeksn = 1,421
Linagliptin is linked with a lower risk of hypoglycemia in humans (hospitalized patients with type 2 diabetes).
Humanshospitalized patients with type 2 diabetes
Canagliflozin
upin humans2
2 studies
Canagliflozin
upin humans2
Canagliflozin raises the risk of hypoglycemia in humans.
Human trial
Canagliflozin raises the risk of hypoglycemia in humans (on background blood glucose-lowering therapy) (modestly higher than placebo).
Human trialon background blood glucose-lowering therapy100 mg and 300 mg26 weeks
Control diet low in plants
upin humans1
1 study
Control diet low in plants
upin humans1
Control diet low in plants raise the risk of hypoglycemia in humans (+0.81% (95% CI, 0.21-1.40) TBR).
Human trial6 monthsn = 226
Control diet low in plants raise the risk of hypoglycemia in humans (prediabetes and overweight/obesity) (0.81% [0.21-1.40], P = 0.024).
Human trialprediabetes and overweight/obesity6 months
All 75Fewer
Trial sponsors
Novartis Pharmaceuticals Corporation
Company1 trialPhase 440 people
Company5 trialsPhase 3285 people
Company5 trialsPhase 3127 people
Company2 trialsPhase 2192 people
Company1 trialPhase 116 people
High Point Clinical Trials Center
Company1 trialPhase 15 people
2 trialsPhase 4190 people
Albert Einstein College of Medicine
2 trialsPhase 443 people
Funding
6 grants since 2018National Institute of Diabetes and Digestive and Kidney Diseases$2.9MNational Institute on Aging$714KUS Department of Veterans Affairs
National Institute of Diabetes and Digestive and Kidney DiseasesVanderbilt University Medical Center$158K2022–2027
A Novel Nitrosylase Prevents Hypoglycemia and Mediates Insulin Resistance
National Institute of Diabetes and Digestive and Kidney DiseasesCase Western Reserve University$506K2024–2027
National Institute on AgingUniversity of California, San Francisco$132K2021–2026
GLP-1 is safe from hypoglycaemia, but why?
European Foundation for the Study of DiabetesKøbenhavns Universitet2023
Glycemic Control: Overtreatment, Hypoglycemia, Mortality and De-Intensification
US Department of Veterans AffairsVa New Jersey Health Care System2016–2020
Severe Hypoglycemia: Ascertainment, Surveillance and Pharmacovigilance
National Institute of Diabetes and Digestive and Kidney DiseasesKaiser Foundation Research Institute$549K2015–2020